You are invited to a presentation on NUPLAZID®:

A Long-Term Care Resident With Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis: A Case for NUPLAZID

Presented virtually by
Daniel J. Cannone, DO
Clinical Professor of Geriatric Medicine
Heritage College of Osteopathic Medicine
Ohio University
Athens, OH
Chief Clinical Consultant
United Church Homes, Inc.
Marion, OH

Meeting Details
Thursday, October 15, 2020 | 7:00 PM EST
For your convenience, please register for this virtual program here or ACADIAPrograms.com below.

Presentation Overview
- Educational information about hallucinations and delusions associated with Parkinson’s disease (PD) psychosis, including:
  - What is PD psychosis?
  - Why does PD psychosis matter?
  - How do I recognize PD psychosis in my residents with PD?
  - How should I approach hallucinations and delusions associated with PD psychosis clinically?
- Review clinical efficacy data and safety profile of NUPLAZID (pimavanserin) 34 mg, the first and only FDA-approved treatment for hallucinations and delusions associated with PD psychosis

Indication
NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Important Safety Information for NUPLAZID (pimavanserin)
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
• Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
• NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.

See additional Important Safety Information located on reverse. Please read the accompanying full Prescribing Information, also available on NUPLAZIDhcp.com.
Important Safety Information for NUPLAZID (pimavanserin) (Cont’d)

• **Contraindication:** NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.

• **QT Interval Prolongation:** NUPLAZID prolongs the QT interval.
  - The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.
  - NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

• **Adverse Reactions:** The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

• **Drug Interactions:**
  - Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
  - Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

**Dosage and Administration**

Recommended dose: 34 mg taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

See Important Safety Information, including **Boxed WARNING**, located on front. Please read the full Prescribing Information attached, also available on [NUPLAZIDhcp.com](http://NUPLAZIDhcp.com).